These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36350309)

  • 1. Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron.
    Black K; Brenn BR; Gaedigk A; Wanderer JP; Van Driest SL
    Clin Transl Sci; 2023 Feb; 16(2):269-278. PubMed ID: 36350309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting.
    Niewiński PA; Wojciechowski R; Śliwiński M; Hurkacz ME; Głowacka K; Orzechowska-Juzwenko K; Wiela-Hojeńska AK
    Adv Clin Exp Med; 2018 Nov; 27(11):1499-1503. PubMed ID: 30058787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series.
    Edwards A; Teusink-Cross A; Martin LJ; Prows CA; Mehta PA; Ramsey LB
    Clin Transl Sci; 2022 Mar; 15(3):610-618. PubMed ID: 34670017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?
    Candiotti KA; Birnbach DJ; Lubarsky DA; Nhuch F; Kamat A; Koch WH; Nikoloff M; Wu L; Andrews D
    Anesthesiology; 2005 Mar; 102(3):543-9. PubMed ID: 15731591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients.
    Wesmiller SW; Henker RA; Sereika SM; Donovan HS; Meng L; Gruen GS; Tarkin IS; Conley YP
    Biol Res Nurs; 2013 Oct; 15(4):382-9. PubMed ID: 22718526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Postoperative Nausea and Vomiting.
    Aroke EN; Hicks TL
    J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
    Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
    Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
    EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.
    Theodosopoulou P; Rekatsina M; Staikou C
    Minerva Anestesiol; 2023 Jun; 89(6):565-576. PubMed ID: 36852569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 genotype and adverse events to risperidone in children and adolescents.
    Oshikoya KA; Neely KM; Carroll RJ; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
    Pediatr Res; 2019 Apr; 85(5):602-606. PubMed ID: 30661084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
    Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
    Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron versus ondansetron for prevention of nausea and vomiting after total abdominal hysterectomy under spinal anesthesia with intrathecal morphine: a double-blind, randomized controlled trial.
    Campos GO; de Jesus Martins M; Jesus GN; de Oliveira PRR; Lessa CN; de Oliveira Junior JCMF; de Castro Alves LJS; Alves RL; Módolo NSP
    BMC Anesthesiol; 2019 Aug; 19(1):159. PubMed ID: 31421679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ondansetron in the prevention of postoperative nausea and vomiting in children.
    Ummenhofer W; Frei FJ; Urwyler A; Kern C; Drewe J
    Anesthesiology; 1994 Oct; 81(4):804-10. PubMed ID: 7943830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population.
    Pietarinen P; Tornio A; Niemi M
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):291-6. PubMed ID: 27038154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
    Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
    Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.
    Rossow KM; Oshikoya KA; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
    J Dev Behav Pediatr; 2021 Apr; 42(3):205-212. PubMed ID: 33759847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
    Kaiser R; Sezer O; Papies A; Bauer S; Schelenz C; Tremblay PB; Possinger K; Roots I; Brockmöller J
    J Clin Oncol; 2002 Jun; 20(12):2805-11. PubMed ID: 12065557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised controlled trial of placebo, droperidol or ondansetron to prevent nausea and vomiting after tonsillectomy in children receiving dexamethasone.
    Flubacher P; Fournier N; Cherpillod J; Waridel F; Nydegger M; Albrecht E
    Anaesthesia; 2017 Jul; 72(7):859-863. PubMed ID: 28449280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.